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Severely affected patients with autonomic failure require pressor agents to counteract the
blood pressure fall and improve presyncopal symptoms upon standing. Previous studies
suggest that combination ergotamine and caffeine may be effective in the treatment of
autonomic failure, but the efficacy of this drug has not been evaluated in controlled trials.
Therefore, we compared the effects of ergotamine/caffeine on seated blood pressure
and orthostatic tolerance and symptoms in 12 primary autonomic failure patients without
history of coronary artery disease. Patients were randomized to receive a single oral dose
of placebo, midodrine (5–10mg), or ergotamine and caffeine (1 and 100mg, respectively) in
a single-blind, crossover study. Blood pressure was measured while patients were seated
and after standing for up to 10min, at baseline and at 1 h post-drug. Ergotamine/caffeine
increased seated systolic blood pressure (SBP), the primary outcome, compared with
placebo (131 ± 19 and 95 ± 12mmHg, respectively, at 1 h post-drug; p = 0.003 for
time effect). Midodrine also significantly increased seated SBP (121 ± 19mmHg at 1 h
post-drug; p = 0.015 for time effect vs. placebo), but this effect was not different from
ergotamine/caffeine (p = 0.621). There was no significant effect of either medication
on orthostatic tolerance; however, ergotamine/caffeine improved presyncopal symptoms
(p = 0.034). These findings suggest that combination ergotamine and caffeine elicits
a seated pressor response that is similar in magnitude to midodrine, and improves
symptoms in autonomic failure. Thus, ergotamine/caffeine could be used as an alternate
treatment for autonomic failure, in carefully selected patients without comorbid coronary
artery disease.
Keywords: autonomic failure, orthostatic hypotension, ergotamine, caffeine, pressor agent
INTRODUCTION
The autonomic nervous system maintains blood pressure dur-
ing standing (Smith et al., 1994; Diedrich and Biaggioni, 2004).
A failure of this system, as in autonomic failure, results in
orthostatic hypotension. Severely affected patients with auto-
nomic failure can only stand for a few seconds to minutes
before developing disabling presyncopal symptoms and even syn-
cope, and often exhibit low blood pressure even in the seated
position. Although non-pharmacologic measures such as phys-
ical counter-maneuvers are the first step in treatment of auto-
nomic failure, pressor agents are often needed in severe patients
to adequately control symptoms (Arnold and Shibao, 2013).
Currently, there are only two drugs approved for treatment
of orthostatic hypotension, the α1-adrenergic agonist mido-
drine and the norepinephrine prodrug droxidopa. The use of
these drugs can be limited by adverse effects, however, and
the FDA recently proposed the withdrawal of midodrine due
to lack of post-marketing evidence to support its clinical effi-
cacy (Dhruva and Redberg, 2010). Thus, there is an emerging
need to identify additional therapeutic options for patients with
autonomic failure.
Previous small studies, ranging from 1 to 10 patients, have
shown that the α-adrenergic agonist ergotamine increases stand-
ing blood pressure and improves symptoms in patients with
orthostatic hypotension when given by inhaled, intramuscular,
or oral routes of administration (Bevegard et al., 1974; Benowitz
et al., 1980; Fouad et al., 1981; Chobanian et al., 1983; Hoeldtke
et al., 1986; Biaggioni et al., 1990). Oral administration of
ergotamine combined with caffeine, to improve its effectiveness
and absorption (Schmidt and Fanchamps, 1974), also improved
standing blood pressure and presyncopal symptoms in a study of
eight autonomic failure patients with parkinsonism and refrac-
tory orthostatic hypotension (Dewey et al., 1998). In this previous
study, however, patients were administered ergotamine/caffeine
in an open-label and uncontrolled fashion. Therefore, the
aim of this study was to systematically evaluate the effect of
ergotamine/caffeine, compared with placebo and the standard
of care midodrine, on seated blood pressure and orthostatic
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A total of 12 primary autonomic failure patients were recruited
from referrals to the Vanderbilt Autonomic Dysfunction Center.
Patients had a documented history of neurogenic orthostatic
hypotension, defined as ≥20mmHg decrease in systolic blood
pressure (SBP) and/or ≥10mmHg decrease in diastolic blood
pressure (DBP) within 3min of standing (Freeman et al., 2011),
and severe autonomic impairment. The consensus criteria from
the American Autonomic Society were used to ascertain the
diagnosis of autonomic failure (Freeman et al., 2011). Eight
patients were diagnosed with pure autonomic failure (PAF),
a primary neurodegenerative disorder characterized by post-
ganglionic autonomic denervation and neurogenic orthostatic
hypotension, 2 patients with Parkinson’s disease (PD+) and
2 with multiple systems atrophy of parkinsonian type (MSA-
P). Patients were excluded if they had secondary causes of
autonomic failure (e.g., diabetes mellitus, amyloidosis, autoim-
mune autonomic ganglionopathy) or had current or history
of coronary artery disease. All procedures were approved by
the Vanderbilt Institutional Review Board and patients pro-
vided written informed consent. This study was registered at
ClinicalTrials.gov under “Treatment of Orthostatic Hypotension
in Autonomic Failure” (NCT00223691).
GENERAL PROTOCOL
Patients were admitted to the Vanderbilt General Clinical
Research Center, and placed on a low-monoamine, caffeine-free,
diet containing 150mEq sodium and 60–80mEq potassium per
day, for at least 3 days before evaluation. All patients under-
went a comprehensive medical history and physical examina-
tion. Medications affecting the autonomic nervous system and
blood volume (such as fludrocortisone) were withheld for at least
five half-lives before admission. Both PD+ patients, however,
remained on carbidopa/levodopa (sinemet) for the duration of
their inpatient stay due to safety concerns. All patients were evalu-
ated with standardized autonomic function tests (e.g., orthostatic
stress, sinus arrhythmia, Valsalva maneuver, hyperventilation,
cold pressor, and isometric handgrip tests) (Low, 2003; Okamoto
et al., 2012). Orthostatic stress testing was consistently performed
starting at 8 a.m. to avoid circadian differences in hemodynamic
and biochemical measures. Blood pressure and heart rate were
measured after patients were supine for at least 30min and again
after 1, 3, 5, and 10min of standing, or as long as tolerated,
using an automated brachial sphygmomanometer cuff (Dinamap
ProCare 100, GE Healthcare). Supine and standing blood samples
were collected from an antecubital vein catheter, placed at least
30min before testing, formeasurement of plasma norepinephrine
by HPLC with electrochemical detection (Goldstein et al., 1988).
ACUTE MEDICATION TRIALS
Autonomic failure patients participated in a crossover study with
oral placebo, 5 or 10mg midodrine (Shire PLC) and combina-
tion 1mg ergotamine and 100mg caffeine (Cafergot, Novartis
Pharmaceuticals) administered on separate days. The doses of
midodrine and ergotamine/caffeine have been previously shown
to elicit pressor responses in autonomic failure patients (Low
et al., 1997; Dewey et al., 1998; Wright et al., 1998). Patients were
administered the dose of midodrine that they were prescribed to
regularly take at home, reflecting standard of care. There were
four patients that received the 5mg dose (2 PAF, 2MSA) and eight
patients that received the 10mg dose (6 PAF, 2 PD+). The order of
medications was randomized using computer generated random
numbers, and was blinded to patients (single-blind).
Acute medication trials were conducted at least 2 h after meals
to avoid post-prandial hemodynamic effects, and in post-void
state. Patients were seated in a chair with their feet on the floor,
consistent with our previous trials of pressor agents in auto-
nomic failure (Jordan et al., 1998; Shibao et al., 2010; Okamoto
et al., 2012). Blood pressure was measured using an automated
brachial sphygmomanometer cuff placed on the right arm, and
heart rate by continuous ECG (Dinamap). Data were digitally
acquired into a custom database (Microsoft Access, Microsoft
Corporation). During baseline, seated blood pressure and heart
rate were measured every 5min for 30min. Orthostatic toler-
ance was assessed by measuring blood pressure and heart rate
after 1, 3, 5, and 10min of standing, or as long as tolerated.
Patients were then asked to sit and were given the study medi-
cation with 50ml tap water. Seated blood pressure and heart rate
were measured every 5min for 60min after drug administration,
with orthostatic tolerance assessed at the end of this period. We
assessed blood pressure at 60min post-drug as it corresponds
to the peak effect of midodrine on standing blood pressure in
autonomic failure (Wright et al., 1998), and the time for peak
plasma levels of ergotamine (Silberstein and McCrory, 2003).
Ergotamine has been shown, however, to improve orthostatic
hypotension and symptoms up to 2 h after oral or inhaled admin-
istration in autonomic failure (Biaggioni et al., 1990; Dewey et al.,
1998). Patients were asked to self-rate the severity of presyn-
copal symptoms at the end of baseline and post-drug standing
periods using a validated orthostatic symptom score (Kaufmann
et al., 2012). This score comprises 6 symptoms: (1) dizziness,
light-headedness, feeling faint or feeling like you might black
out; (2) problems with vision (blurring, seeing spots, tunnel
vision); (3) generalized weakness; (4) fatigue; (5) trouble con-
centrating; and (6) head/neck discomfort. These symptoms are
rated individually in terms of severity on a scale of 0 to 10, with
0 reflecting absence of symptoms. Changes in composite symp-
tom scores from baseline to 60min post-drug were compared for
each medication. In addition, changes in scores from Question
1 (lightheadedness), the symptom most commonly described by
patients with orthostatic hypotension (Kaufmann et al., 2012;
Shibao et al., 2012), were compared for each medication from
baseline to 60min post-drug. All procedures were performed
by trained research nurses and in accordance with institutional
guidelines.
STATISTICAL ANALYSIS
We tested the null hypothesis that there is no difference
in seated blood pressure following placebo, midodrine, and
ergotamine/caffeine administration in autonomic failure. The
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primary outcome was defined a priori as the seated SBP during
the 60-min post-drug period, with adjustment for average seated
SBP at baseline. Baseline and post-drug seated SBP values were
logarithmic transformed to reduce skewness in their distribu-
tion. A random effects model with random intercept and random
slope for time was used to examine for differences in the mean
log seated SBP during the 60-min post-drug period among treat-
ment groups. The following terms were included in the model:
treatment group, time, time and treatment interaction, and aver-
age seated SBP at baseline. Differences in baseline seated SBP
among study days were compared with Friedman non-parametric
tests. Differences in the seated pressor response between mido-
drine and ergotamine/caffeine were compared using a McNemar
non-parametric test. Secondary outcomes included orthostatic
tolerance and presyncopal symptoms measured by the orthostatic
symptoms score. Orthostatic tolerance was defined as area under
the curve for standing SBP calculated by the trapezoidal rule
(AUCSBP: upright SBP multiplied by standing time). The differ-
ence in the AUCSBP between baseline and post-drug (AUCSBP)
was used to test whether orthostatic tolerance differed among
treatment groups using a random effects model. Comparisons
were made only for patients who could stand after all active med-
ications. Differences in orthostatic symptom scores from baseline
to 60min post-administration were compared within each indi-
vidual drug using Wilcoxon signed-rank non-parametric tests.
Data are presented asmean± 95% confidence interval (CI) unless
otherwise specified. All tests were two-tailed, and a p-value< 0.05
was considered significant. Analyses were performed with SPSS
(version 22.0, IBMCorporation, Chicago, IL) and STATA (version
12.0, StataCorp, College Station, TX).
Sample size calculations were performed using paired t-test
analysis in PS software (Version 3.0.34) (Dupont and Plummer,
1990). A blinded analysis was performed on preliminary data
obtained from the first 3 patients enrolled in this study to obtain
an estimate of variance, and showed an approximate 17mmHg
standard deviation of difference in seated SBP among treatment
groups. An increase in seated blood pressure of 20mmHg would
be a clinically meaningful difference, representing the approxi-
mate magnitude of response achieved with other vasoconstrictor
drugs (Jordan et al., 1998). Based on these data, we estimated
that 10 patients would have 90% power to detect a difference
in means among treatment groups. Since sample size calcula-
tions were performed using parametric tests, we increased the
sample size by 15% to account for analysis of outcomes with
non-parametric methods. Thus, 12 patients were included in this
study.
RESULTS
RESTING CARDIOVASCULAR AUTONOMIC FUNCTION
Patient clinical characteristics are shown in Table 1. During
screening, two patients (1 PAF, 1 PD+) were unable to stand
for 1min during the orthostatic stress testing due to presyncopal
symptoms (Table 2). The remaining 10 patients exhibited pro-
found decreases in SBP and DBP after 1min of standing, without
an adequate compensatory increase in heart rate. Autonomic fail-
ure patients had severe sympathetic and parasympathetic impair-
ment compared with healthy subjects as indicated in Table 3
Table 1 | Patient clinical characteristics.
Patient Diagnosis Sex BMI Age Disease duration
(kg/m2) (years) (years)
1 PAF M 25 83 7
2 PAF M 30 47 6
3 PAF M 34 65 2
4 PAF M 29 70 2
5 PD+ F 20 71 10
6 PAF F 23 70 2
7 MSA-P M 33 57 2
8 PAF M 25 69 8
9 PAF F 26 65 10
10 PAF M 30 65 6
11 PD+ F 22 56 7
12 MSA-P M 32 52 4
BMI, body mass index; PAF, pure autonomic failure; PD+, Parkinson’s disease
with autonomic failure; MSA-P, multiple systems atrophy with parkinsonian
features.
Table 2 | Orthostatic stress testing.
Patient Blood pressure Heart rate Plasma NE
(mmHg) (bpm) (pg/ml)
Supine Upright Supine Upright Supine Upright
1 182/85 114/62 61 68 106 200
2 148/100 70/45 71 81 38 67
3 111/59 66/46 74 111 117 140
4 139/87 65/47 62 86 25 84
5 139/74 88/47 78 98 55 44
6 159/69 66/40 74 103 219 306
7 119/77 83/61 69 81 251 540
8 112/65 66/41 69 75 30 22
9 95/64 - -/- - 93 - - 378 - -
10 127/83 95/61 70 82 122 303
11 86/64 - -/- - 77 - - 274 - -
12 136/87 94/58 85 85 135 184
Hemodynamic measurements and blood samples were obtained while patients
were supine (at least 30min) and upright (after 1min of standing). Blood pres-
sure values represent systolic/diastolic. NE, norepinephrine; - -, patient was
not able to stand for 1min to obtain hemodynamic measurements and blood
samples due to presyncopal symptoms.
by: (a) reduced sinus arrhythmia ratio; (b) reduced Valsalva
maneuver heart rate ratio; (c) exaggerated depressor response
during phase II and absence of blood pressure overshoot dur-
ing phase IV of the Valsalva maneuver; and (d) impaired pressor
responses to isometric handgrip exercise or pain stimulus (cold
pressor test).
PRESSOR RESPONSE TO DRUGS
The average seated SBP during the 30-min baseline period
was similar among placebo, ergotamine/caffeine, and mido-
drine study days (p = 0.441; Friedman test). Ergotamine/caffeine
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Table 3 | Autonomic function tests.
Patient SA ratio Valsalva ratio Valsalva Valsalva HVTN SBP Cold pressor SBP Handgrip SBP
phase II SBP phase IV SBP†
1 1.07 1.11 −77 −22 - - - - - -
2 1.01 0.95 −62 −50 −42 −10 9
3 1.04 1.07 −88 −42 −37 5 3
4 1.05 1.01 −71 −42 −7 −3 −7
5 1.05 1.06 −29 −60 −26 5 3
6 1.02 1.17 −140 −69 −81 - - 30
7 1.08 1.05 −70 −36 −28 −2 6
8 1.19 1.48 −29 −24 - - - - - -
9 1.01 1.03 −146 −97 −53 4 −26
10 1.14 1.13 −38 −23 −10 11 10
11 1.01 1.18 −55 −46 −11 8 2
12 1.00 1.01 −50 −38 −34 3 8
Healthy 1.20 ± 0.1 1.50 ± 0.2 ≤20 >20 −5 ± 6 24 ± 13 16 ± 6
Data for autonomic function testing are reported as changes in systolic blood pressure (SBP) compared with baseline. Data for healthy subjects are presented as
mean ± SD and were obtained from the Vanderbilt Autonomic Dysfunction Center database. SA, sinus arrhythmia; HVTN, hyperventilation. †A negative value for
phase IV of the Valsalva maneuver indicates that the blood pressure overshoot was absent. - -, patient was not able to tolerate test.
significantly increased seated SBP, the primary outcome, as a
linear function of time compared with placebo (Figure 1; slope
difference: 1.003; 95% CI: 1.001 to 1.005; p = 0.003; random
effects model). Similarly, midodrine increased seated SBP com-
pared with placebo (Figure 1; slope difference: 1.002; 95% CI:
1.001–1.004; p = 0.015; random effects model). The magnitude
of the seated pressor response to midodrine was similar between
patients receiving the 5mg (median: 26; IQR: 14–36) and 10mg
(median: 23; IQR: 7–48) doses. There was no significant dif-
ference, however, in the seated pressor response between ergo-
tamine/caffeine and midodrine (slope difference: 1.000; 95% CI:
0.998–1.001; p = 0.621; random effects model). In this study, 9
out of 12 (75%) patients exhibited an increase in seated SBP ≥
20mmHg with ergotamine/caffeine compared with 5 out of 12
(42%) patients for midodrine, a difference that was not signifi-
cantly different (p = 0.125; McNemar test).
ORTHOSTATIC TOLERANCE AND SYMPTOMS
As shown in Figure 2, at 60min after placebo administration
5 out of 12 (42%) autonomic failure patients could stand
for 10min, compared with 8 out of 12 (67%) after ergo-
tamine/caffeine and 6 out of 12 (50%) after midodrine. There
was no significant difference, however, in orthostatic tolerance
between ergotamine/caffeine and placebo (AUCSBP: 248; 95%
CI: −73 to 568; p = 0.130; random effects model), between
midodrine and placebo (AUCSBP: 85; 95% CI: −141 to
311; p = 0.461), or between ergotamine/caffeine and midodrine
(AUCSBP: −163; 95% CI: −387 to 62; p = 0.155). The ortho-
static symptom composite score, as well as the lightheadedness
component of this score (Question 1), were reduced at 60min fol-
lowing ergotamine/caffeine administration (Figure 3; p = 0.034
and 0.040, respectively; Wilcoxon signed-rank test) when com-
pared with baseline. In contrast, there was no significant effect
of either midodrine or placebo on orthostatic symptom scores
(Figure 3).
FIGURE 1 | Changes in seated blood pressure following drug
administration. The combination of 1mg ergotamine and 100mg caffeine
increased seated systolic blood pressure over time compared with placebo
in patients with severe autonomic failure (p = 0.003). Similarly, 5–10mg
midodrine increased seated systolic blood pressure in these patients
(p = 0.015), but this effect was not different from ergotamine/caffeine
(p = 0.621). Data are presented as mean ± 95% confidence interval.
DISCUSSION
The main finding of this study is that combination ergotamine
and caffeine improves seated blood pressure in patients with
severe autonomic failure, to a similar extent as the standard of
care pressor agent midodrine. Furthermore, while there was no
significant effect of either drug on orthostatic tolerance, ergo-
tamine/caffeine improved presyncopal symptoms upon standing.
These findings suggest that the combination of ergotamine and
caffeinemay be useful for the treatment of autonomic failure, par-
ticularly in patients without underlying vascular disease and who
are unable to tolerate midodrine.
Autonomic failure is associated with sympathetic denervation
and impaired baroreflex-mediated arteriolar vasoconstriction,
leading to excessive venous pooling and reduced venous return to
the heart upon assumption of the upright position. The periph-
eral α1-adrenergic agonist midodrine increases systemic vascular
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FIGURE 2 | Orthostatic tolerance following drug administration. At
60min following drug administration, autonomic failure patients were asked
to stand for 10min, or as long as tolerated. Systolic blood pressure was
measured at 1, 3, 5, and 10min to assess orthostatic tolerance. Blood
pressure data and standing time are shown for each individual patient, with
N representing the number of patients who could tolerate standing at a
given time point. Five out of 12 (42%) patients could stand for 10min
following placebo (A) compared with 8 out of 12 (67%) after ergotamine/
caffeine (B) and 6 out of 12 (50%) after midodrine (C) administration.
resistance, and has demonstrated efficacy to elevate blood pres-
sure and improve presyncopal symptoms in autonomic failure
(Schirger et al., 1981; Kaufmann et al., 1988; Jankovic et al.,
1993; Fouad-Tarazi et al., 1995; Low et al., 1997; Wright et al.,
FIGURE 3 | Effect of drugs on orthostatic presyncopal symptoms. Data
represent changes in orthostatic symptom scores from baseline (left bar) to
60min post-administration (right bar), with comparisons made for each
individual drug. (A) Combination 1mg ergotamine and 100mg caffeine
reduced the orthostatic symptom composite score in autonomic failure
patients, suggesting an improvement in presyncopal symptom burden. In
contrast, there was no effect of 5–10mg midodrine or placebo on this
composite score. (B) Combination ergotamine and caffeine also reduced
the lightheadedness component (Question 1) of the orthostatic symptoms
score in these patients, with no significant effect of midodrine or placebo.
Data are presented as mean ± 95% confidence interval.
1998). The increase in seated SBP with midodrine was similar
in magnitude to a previous report in seated patients (Jordan
et al., 1998), and to the effects of chronic administration on
standing blood pressure (Jankovic et al., 1993). The use of mido-
drine is limited in some patients by adverse effects such as
pilomotor reactions, pruritus of the scalp, urinary urgency or
retention, and supine hypertension (Fouad-Tarazi et al., 1995;
Low et al., 1997). We also recently reported poor persistence on
treatment with midodrine in patients with neurogenic ortho-
static hypotension (Shibao et al., 2013a). Furthermore, not all
patients respond to midodrine, with a previous report showing
a pressor effect in 69% and 38% of PD+ and MSA patients,
respectively (Jankovic et al., 1993). Similarly, in this study only
42% of autonomic failure patients had a significant pressor
response to midodrine. These findings illustrate the need to iden-
tify additional therapeutic options for the treatment of autonomic
failure.
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In addition to potent vasoconstriction, ergotamine elic-
its peripheral venoconstriction through stimulation of α-
adrenoreceptors (Fouad et al., 1981; Chobanian et al., 1983).
Ergotamine/caffeine could be more effective than midodrine
in this regard by improving venous return, but this was not
observed. There was a high response rate to ergotamine/caffeine
with 75% of patients in this study and 100% of patients in a previ-
ous study (Dewey et al., 1998) exhibiting a greater than 20mmHg
increase in seated and standing blood pressure, respectively. Some
long-term benefit of ergotamine/caffeine to reduce presyncopal
symptoms and syncopal episodes has also been demonstrated in
small, uncontrolled studies (Chobanian et al., 1983; Dewey et al.,
1998). It is difficult to predict which patients will respond to
ergotamine/caffeine, however, as an acute test dose did not pre-
dict long-term efficacy in autonomic failure (Dewey et al., 1998).
Furthermore, the severity of autonomic failure, results of auto-
nomic function testing, and plasma catecholamine levels were
shown to be poor predictors of response to pressor agents (Jordan
et al., 1998). The magnitude of pressor responses to midodrine
and ergotamine/caffeine (26 and 36mmHg, respectively) likely
reflects loss of baroreflex buffering, butmay also involve enhanced
adrenergic sensitivity. It is unlikely that caffeine played a major
role in the seated pressor effect of ergotamine/caffeine treat-
ment, as acute caffeine produces a modest pressor or no effect
in autonomic failure (Onrot et al., 1985; Jordan et al., 1998).
The goal for treatment of autonomic failure is to reduce
presyncopal symptoms and improve standing time, and not to
treat underlying disease. This can be achieved by increasing seated
blood pressure within the range of cerebral autoregulation, so that
cerebral perfusion is maintained even with a fall in blood pressure
during standing. In this study, orthostatic tolerance was defined
as the AUC for standing SBP, to take into account not only blood
pressure levels but also total standing time, similar to our previous
studies (Shibao et al., 2010; Okamoto et al., 2012). Midodrine and
ergotamine have both been shown to improve standing time and
presyncopal symptoms in autonomic failure (Chobanian et al.,
1983; Kaufmann et al., 1988; Biaggioni et al., 1990; Jankovic et al.,
1993; Fouad-Tarazi et al., 1995; Low et al., 1997; Dewey et al.,
1998; Wright et al., 1998), perhaps suggesting that this study was
underpowered to detect differences in measures of orthostatic
tolerance.
In this study, five patients were discharged on ergo-
tamine/caffeine, of which three continued taking this medi-
cation in combination with other pressor agents (e.g., mido-
drine, pyridostigmine). Two patients subsequently stopped tak-
ing ergotamine/caffeine, one due to side effects (feeling tense)
and the other because the medication was not readily avail-
able. A previous study also reported nausea and tachyphylaxis
with chronic administration in autonomic failure (Dewey et al.,
1998). Importantly, ergotamine can produce vascular complica-
tions such as arterial vasospasm (ergotism) and valvular heart
disease. There was no evidence of vascular complications with
chronic ergotamine/caffeine in autonomic failure (Dewey et al.,
1998), even at doses reported to cause ergotism in migraine
patients (Bigal and Tepper, 2003). There is limited data, how-
ever, on long-term safety and efficacy for treatment of orthostatic
hypotension. Thus, this drug is recommended only in carefully
selected patients without evidence of coronary or peripheral
artery disease.
At least half of autonomic failure patients also have para-
doxic supine hypertension (Biaggioni and Robertson, 2002). The
ideal pressor agent in these patients would prevent the fall in
blood pressure with standing, without increasing supine or seated
blood pressure. There have been no drugs to date, however, that
have met this criteria. Initial studies showed that ergotamine
preferentially increases standing blood pressure in patients with
orthostatic hypotension (Jennings et al., 1979; Olver et al., 1980),
but this has not been a consistent finding with reports of lim-
iting supine hypertension (Chobanian et al., 1983; Dewey et al.,
1998). We did not measure supine blood pressure in this study
for safety reasons, but similar to other short-acting pressor agents,
the use of ergotamine/caffeine should be limited to morning and
early afternoon with avoidance of the supine position for at least
4 h after each dose, following recent standard of care guidelines
(Shibao et al., 2013b).
There are some potential limitations to this study. First, auto-
nomic failure patients were enrolled at a tertiary care center for
autonomic disorders and may not reflect the broader and less
severe disease population. Second, this study included a relatively
small number of patients, but was similar in sample size to pre-
vious studies of pressor agents in autonomic failure. This study
was powered to detect an increase in seated SBP, the primary
outcome; however, secondary outcomes including orthostatic tol-
erance may have reached significance with additional patients.
Third, we were not able to evaluate standing blood pressure as our
primary endpoint, as most patients are only able to stand for a few
seconds to minutes due to disabling presyncopal symptoms. The
seated position provides a well-tolerated postural stress in these
patients that allows for evaluation over prolonged time periods,
and in most patients we have found that the acute seated pres-
sor response is a reasonable predictor of long-term symptomatic
efficacy.
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